Election Day 2018 has come and gone, and a new class of legislators will be joining the ranks of Congress in January. RheumPAC is the most important tool we have to establish relationships with our new legislators and this year, our ACR volunteer leaders stepped up and matched all donations to RheumPAC leading up to…
Genetic Discoveries Pave New Pathways to the Origins of Rheumatic Diseases
New research has provided a never-before-seen view of the genetic activity that may be used to map the polygenic nature of common rheumatic diseases. Two recent studies have employed distinct approaches to identify the non-coding gene variants, digging deep into human genetic data to uncover the mechanism of rheumatic diseases…
Mirtazapine Ineffective for Fibromyalgia
Mirtazapine has been prescribed off-label to fibromyalgia patients who have not responded to other treatments. However, a recent systemic review found no difference between mirtazapine and placebo for these patients, and any potential benefits from mirtazapine may not outweigh its potential harm, including drowsiness, weight gain and liver damage…
In Memoriam: Mart Mannik, MD
Mart Mannik, MD, professor emeritus, Division of Rheumatology at the University of Washington (UW), passed away on Wednesday, Aug. 22, 2018. Dr. Mannik was born in Estonia and came to the U.S. at age 12 as a refugee from World War II. He received his medical degree from Western Reserve University School of Medicine in…
CMS Proposes New Part B Drug Payment Model
Late last month, the Centers for Medicare & Medicaid Services (CMS) released an advance notice of proposed rulemaking (ANPRM), seeking feedback on a potential drug pricing model called the International Pricing Index (IPI) model. This comment solicitation is in alignment with the administration’s blueprint to lower drug costs and reduce out-of-pocket costs, and is an…
Gene Therapy for OA
Background & objective: One of the major challenges in the treatment of chronic joint diseases, such as osteoarthritis (OA), is the need to provide sustained bioavailability of a therapeutic agent within the joint. Systemically administered drugs cannot sufficiently reach the synovial space, and intra-articularly injected agents are cleared from the joint fluid rapidly by the…
How to Engage Young Adult Patients
Gaps in healthcare are common between the ages of 17 and 21. But simple collaborations between adult and pediatric rheumatologists can go a long way to help young adults stay engaged in their rheumatology care…
Sjögren’s Syndrome: Beyond Dryness
CHICAGO—Diagnostic and treatment tips on Sjögren’s syndrome from the experts at the 2018 ACR/ARHP Annual Meeting.
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
Central Sensitization to Pain May Not Predict Long-Term Outcomes after Carpal Tunnel Release Surgery
Pain sensitization, such as that experienced by patients with carpal tunnel syndrome (CTS), has been associated with poorer clinical outcomes after surgery. New research has found that, although pain sensitization in CTS patients correlates with preoperative symptom severity, CTS symptoms did not have a persistent effect on functional outcomes after surgery…
- « Previous Page
- 1
- …
- 285
- 286
- 287
- 288
- 289
- …
- 798
- Next Page »